MULTIDRUG RESISTANCE PROTEIN: P-GLYCOPROTEIN - Drug Transporters: Molecular Characterization and Role in Drug Disposition - page 260

192. Mayer U, Wagenaar E, Dorobek B, Beijnen JH, Borst P, Schinkel AH. 1997. Full blockade
of intestinal P-glycoprotein and extensive inhibition of blood-brain barrier P-glycoprotein
by oral treatment of mice with PSC833. J Clin Invest 100:2430-2436.
193. Hendrikse NH, Schinkel AH, De Vries EGE, Fluks E, van der Graaf WTA, Willemsen
ATM, Vaalburg W, Franssen EJF. 1998. Complete in vivo reversal of P-glycoprotein pump
function in the blood-brain barrier visualized with positron emission tomography. Br J
Pharmacol 124:1413-1418.
194. Tan B, Piwnica-Worms D, Ratner L. 2000. Multidrug resistance transporters and modu-
lation. Curr Opin Oncol 12:450-458.
195. Litman T, Druley TE, Stein WD, Bates SE. 2001. From MDR to MXR: new understanding
of multidrug resistance systems, their properties and clinical significance. Cell Mol Life
Sci 58:931-959.
196. Leith CP, Kopecky KJ, Godwin J, McConnell T, Slovak ML, Chen IM, Head DR, Ap-
pelbaum FR, Willman CL. 1997. Acute myeloid leukemia in the elderly: assessment of
multidrug resistance (MDR1) and cytogenetics distinguishes biologic subgroups with
remarkably distinct responses to standard chemotherapy. A Southwest Oncology Group
study. Blood 89:3323-3329.
197. Leith CP, Kopecky KJ, Chen IM, Eijdems L, Slovak ML, McConnell TS, Head DR, Weick
J, Grever MR, Appelbaum FR, Willman CL. 1999. Frequency and clinical significance
of the expression of the multidrug resistance proteins MDR1/P-glycoprotein, MRP1, and
LRP in acute myeloid leukemia: a Southwest Oncology Group Study. Blood 94:1086-
1099.
198. Garraway LA, Chabner B. 2002. MDRI inhibition: less resistance or less relevance? Eur
J Cancer [A] 38:2337-2340.
199. Polgar O, Bates SE. 2005. ABC transporters in the balance: Is there a role in multidrug
resistance? Biochem Soc Trans 33:241-245.
200. Gottesman MM. 2002. Mechanisms of cancer drug resistance. Annu Rev Med 53:615-
627.
201. Chen CC, Meadows B, Regis J, Kalafsky G, Fojo T, Carrasquillo JA, Bates SE. 1997.
Detection of in vivo P-glycoprotein inhibition by PSC 833 using Tc-99m sestamibi. Clin
Cancer Res 3:545-552.
202. Scotto KW. 2003. Transcriptional regulation of ABC drug transporters. Oncogene
22:7496-7511.
203. Labialle S, Gayet L, Marthinet E, Rigal D, Baggetto LG. 2002. Transcriptional regulators
of the human multidrug resistance 1 gene: recent views. Biochem Pharmacol 64:943-
948.
204. Shtil AA, Azare J. 2005. Redundancy of biological regulation as the basis of emergence
of multidrug resistance. Int Rev Cytol 246:1-29.
205. Chin JE, Soffir R, Noonan KE, Choi K, Roninson IB. 1989. Structure and expression of
the human MDR (P-glycoprotein) gene family. Mol Cell Biol 9:3808-3820.
206. Schwab M, Eichelbaum M, Fromm MF. 2003. Genetic polymorphisms of the human
MDR1 drug transporter. Annu Rev Pharmacol Toxicol 43:285-307.
207. Fromm MF. 2002. The influence of MDR1 polymorphisms on P-glycoprotein expression
and function in humans. Adv Drug Deliv Rev 54:1295-1310.
208. Pauli-Magnus C, Kroetz DL. 2004. Functional implications of genetic polymorphisms in
the multidrug resistance gene MDR1 ( ABCB1 ). Pharm Res 21:904-913.